Invitrogen™ SARS-CoV-2 Alpha Spike Protein RBD Chimeric Recombinant Human Monoclonal Antibody (D004)

Beschreibung

Specifically recognize the SARS-CoV-2 Alpha Spike RBD and ECD. No cross-reactivity with SARS-CoV-2, Beta, Delta, Omicron BA.4/BA.5/BA.5.2, Omicron BA.2.75 variant. Has Medium cross-reactivity in ELISA with SARS-CoV-2 wild type Spike RBD.. Has cross-reactivity in ELISA with: SARS-CoV-2 Alpha (B.1.1.7) Spike S1+S2 trimer Protein; SARS-CoV-2 Alpha (B.1.1.7) Spike RBD Protein; Has Medium cross-reactivity in ELISA with: SARS-CoV-2 Spike RBD Protein; No cross-reactivity in ELISA with: SARS-CoV-2 Omicron (XBB.1.16) Spike S1+S2 trimer Protein; SARS-CoV-2 Omicron (XBB.1.5) Spike RBD Protein; SARS-CoV-2 Omicron (XBB.1.5) Spike S1+S2 trimer Protein; SARS-CoV-2 Omicron (XBB.1) Spike S1+S2 trimer Protein; SARS-CoV-2 Omicron (XBB) Spike RBD Protein; SARS-CoV-2 Omicron (BQ.1.1) Spike S1+S2 trimer Protein; SARS-CoV-2 Omicron (BQ.1.1) Spike RBD Protein; SARS-CoV-2 Omicron (BF.7) Spike S1+S2 trimer Protein; SARS-CoV-2 Omicron (BA.4.6/BF.7) Spike RBD Protein; SARS-CoV-2 Omicron (BA.4.6) Spike S1+S2 trimer Protein; SARS-CoV-2 Omicron (BA.4/BA.5/BA.5.2) Spike S1+S2 trimer Protein; SARS-CoV-2 Omicron (BA.4/BA.5/BA.5.2) Spike RBD Protein; SARS-CoV-2 Omicron (BA.2.75) Spike RBD Protein; SARS-CoV-2 Omicron (BA.2.75) Spike S1+S2 trimer Protein; SARS-CoV-2 Omicron (BA.2.75.2) Spike RBD Protein; SARS-CoV-2 Omicron (BA.2.75.2) Spike S1+S2 trimer Protein; SARS-CoV-2 Omicron (BA.2.75) Spike RBD Protein; SARS-CoV-2 Omicron (BA.2.3.20) Spike RBD Protein; SARS-CoV-2 Omicron (B.1.1.529) S1+S2 trimer Protein...

The SARS-CoV-2 Alpha Spike Protein RBD refers to the receptor-binding domain (RBD) of the spike (S) protein found in the Alpha variant of the SARS-CoV-2 virus, which is responsible for COVID-19. The RBD is a crucial region within the S1 subunit of the spike protein that specifically binds to the angiotensin-converting enzyme 2 (ACE2) receptor on the surface of human cells, facilitating viral entry. The Alpha variant, first identified in the UK, has several mutations in the spike protein, including in the RBD, which can enhance the virus's ability to bind to ACE2, potentially increasing its transmissibility and impacting the effectiveness of immune responses. Understanding these mutations is vital for developing and adjusting vaccines and therapeutic strategies.